Navigation Links
Signals found that recruit host animals' cells, enabling breast cancer metastasis
Date:5/22/2014

Working with mice, Johns Hopkins researchers report they have identified chemical signals that certain breast cancers use to recruit two types of normal cells needed for the cancers' spread. A description of the findings appears in the online early May edition of the Proceedings of the National Academy of Sciences.

"Blocking one of these cell-recruiting signals in a mouse's tumor made it much less likely to metastasize or spread," says Gregg Semenza, M.D., Ph.D., a professor and director of the Vascular Biology Program in the Johns Hopkins University School of Medicine's Institute for Cell Engineering. "If a drug can be found that safely blocks the same signal in humans, it could be a very useful addition to current breast cancer treatment particularly for patients with chemotherapy-resistant tumors."

Semenza's research group studies a chemical signal called hypoxia-inducible factor 1 (HIF-1), which cells release to help them cope with low-oxygen conditions. Earlier, the group determined that HIF-1 helps breast tumor cells survive the low-oxygen conditions in which they often live, and spread to other parts of the body such as the lungs. "In breast cancer, it's not the original tumor that kills patients, but the metastases," says Semenza.

Also in a previous study, Semenza's group found that HIF-1 induced adult stem cells called mesenchymal stem cells release a signal to nearby breast cancer cells, which made them more likely to spread. The researchers suspected this communication might run both ways and that the stem cells' presence might also help the cancer to recruit the host animal's white blood cells. Breast cancers need the support of several types of host cells in order to metastasize, including mesenchymal stem cells and one type of white blood cell, Semenza notes.

Studying tumor cells grown in a dish, Semenza's team used chemicals that blocked the functions of various proteins to map a web of signals flying among breast cancer cells, menenchymal stem cells and white blood cells. One positive feedback loop brought mesenchymal stem cells close in to the breast cancer cells. A separate loop of signals between the stem cells and cancer cells caused the cancer cells to release a chemical "beacon" that drew in white blood cells. The concentrations of all the signals in the web were increased by the presence of HIF-1 and ultimately, by low-oxygen conditions.

The team then used genetic engineering to reduce the levels of the cell-recruiting signals in breast cancer cells and implanted those cells into female mice. Compared with unaltered breast cancer cells, those with reduced recruiting power grew into similar-sized tumors, Semenza says, but were much less likely to spread.

All of the breast cancer cells used in the study were so-called triple-negative, meaning they lack receptors for estrogen, progesterone and human epidermal growth factor receptor 2, so they do not respond to therapies that target those receptors. In people, triple-negative breast cancers also tend to be more deadly than other breast cancers because they contain more HIF-1, Semenza says. "This study adds to the evidence that a HIF-1 inhibitor drug could be an effective addition to chemotherapy regimens, especially for triple-negative breast cancers," he says. Several potential drugs of this kind are now in the early stages of development, he notes.


'/>"/>

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine
Source:Eurekalert

Related medicine news :

1. Molecular aberration signals cancer
2. Tinnitus study signals advance in understanding link between loud sounds exposure and hearing loss
3. Long distance signals protect brain from viral infections
4. BioPharm Systems to Host Webinar on Evaluating and Investigating Drug Safety Signals with Public Databases
5. Protein in prostate biopsies signals increased cancer risk
6. Pleasure and pain brain signals disrupted in fibromyalgia patients
7. Disney researchers use encoded audio signals to provide second screen experiences at most venues
8. Self-perpetuating signals may drive tumor cells to spread
9. One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS
10. Turning Alzheimers fuzzy signals into high definition
11. Autism Speaks trailblazer study -- Blocking cell distress signals can ease autism symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 2017 , ... MarkeTouch Media has partnered with fred’s Pharmacy ... modern design with a more streamlined user experience and is designed to improve ... includes hundreds of digital coupons that can be clipped to a customer’s account ...
(Date:9/19/2017)... ... 2017 , ... With Netmail Hadron, construction companies ... States, can easily manage all of their data, apply policies on that data, ... “As a construction company,” says Ryan Sinnwell, the Infrastructure Manager at The Weitz ...
(Date:9/18/2017)... ... September 19, 2017 , ... Sarantos For The ... This December , Sarantos is proud to be the 1st (and continues to be ... song release. A new song, music video, book chapter and behind the scenes video ...
(Date:9/18/2017)... ... September 18, 2017 , ... A September 7 article ... that aspirin, one of the world’s most common and least expensive medications, may be ... dentist Dr. Farzad Feiz of California Dental Group and Calabasas Dental Care says that, ...
(Date:9/18/2017)... ... September 18, 2017 , ... Altec Products, Inc., ... DocLink Advanced Admin Training in Irvine, CA. The four-day training session, which ... that will allow them to manage DocLink more efficiently and effectively. , Covering ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... Lilly and Company (NYSE: LLY ) will ... an investigational, oral, first-in-class molecule for the acute treatment ... placebo in the Phase 3 SPARTAN study. Detailed results ... the International Headache Society (IHC) in Vancouver ... lasmiditan,s potential to reduce pain and provide freedom from ...
(Date:9/7/2017)... Sept. 7, 2017 Caris Life Sciences, ... fulfilling the promise of precision medicine, today announced ... benefits of its molecular profiling approach in guiding ... genomic profiling plus (CGP+) with Caris Molecular Intelligence ... on a molecular level, leading to more therapeutic ...
Breaking Medicine Technology: